Abeona Therapeutics (ABEO) revenue and earnings history
Abeona Therapeutics reported revenue of $5.82M for fiscal 2025 (year ended Dec 31, 2025), and net income of $71.2M.
Over 15 years, from fiscal 2010 to fiscal 2025, revenue grew at a compound rate of +18.1% a year.
Revenue and net income, 16 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $5.82M | −$89.4M | $71.2M | −$76.3M | $7.97M | −$84.3M | $10.8M | — | — | $78.4M | $20M | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Abeona Therapeutics (ABEO) on OQRO.
Common questions
What was Abeona Therapeutics's revenue in fiscal 2025?
$5.82M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 17, 2026.
How fast has Abeona Therapeutics's revenue grown?
From $481K in fiscal 2010 to $5.82M in fiscal 2025: a compound annual growth rate of +18.1% over 15 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Abeona Therapeutics been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Abeona Therapeutics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
